Literature DB >> 29227443

Associations Between Medicare Part D and Out-of-Pocket Spending, HIV Viral Load, Adherence, and ADAP Use in Dual Eligibles With HIV.

Nadya Belenky1, Brian W Pence1, Stephen R Cole1, Stacie B Dusetzina2,3, Andrew Edmonds1, Jonathan Oberlander3,4, Michael W Plankey5, Adebola Adedimeji6, Tracey E Wilson7, Jennifer Cohen8, Mardge H Cohen9, Joel E Milam10, Elizabeth T Golub11, Adaora A Adimora1,12.   

Abstract

BACKGROUND: The implementation of Medicare part D on January 1, 2006 required all adults who were dually enrolled in Medicaid and Medicare (dual eligibles) to transition prescription drug coverage from Medicaid to Medicare part D. Changes in payment systems and utilization management along with the loss of Medicaid protections had the potential to disrupt medication access, with uncertain consequences for dual eligibles with human immunodeficiency virus (HIV) who rely on consistent prescription coverage to suppress their HIV viral load (VL).
OBJECTIVE: To estimate the effect of Medicare part D on self-reported out-of-pocket prescription drug spending, AIDS Drug Assistance Program (ADAP) use, antiretroviral adherence, and HIV VL suppression among dual eligibles with HIV.
METHODS: Using 2003-2008 data from the Women's Interagency HIV Study, we created a propensity score-matched cohort and used a difference-in-differences approach to compare dual eligibles' outcomes pre-Medicare and post-Medicare part D to those enrolled in Medicaid alone.
RESULTS: Transition to Medicare part D was associated with a sharp increase in the proportion of dual eligibles with self-reported out-of-pocket prescription drug costs, followed by an increase in ADAP use. Despite the increase in out-of-pocket costs, both adherence and HIV VL suppression remained stable.
CONCLUSIONS: Medicare part D was associated with increased out-of-pocket spending, although the increased spending did not seem to compromise antiretroviral therapy adherence or HIV VL suppression. It is possible that increased ADAP use mitigated the increase in out-of-pocket spending, suggesting successful coordination between Medicare part D and ADAP as well as the vital role of ADAP during insurance transitions.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29227443      PMCID: PMC5728680          DOI: 10.1097/MLR.0000000000000843

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   3.178


  17 in total

1.  Transition to Medicare Part D: an early snapshot of barriers experienced by younger dual eligibles with disabilities.

Authors:  Jean P Hall; Noelle K Kurth; Janice M Moore
Journal:  Am J Manag Care       Date:  2007-01       Impact factor: 2.229

2.  Association of unmet needs for support services with medication use and adherence among HIV-infected individuals in the southeastern United States.

Authors:  S Reif; K Whetten; K Lowe; J Ostermann
Journal:  AIDS Care       Date:  2006-05

3.  The differential impact of copayment on drug use in a Medicaid population.

Authors:  C E Reeder; A A Nelson
Journal:  Inquiry       Date:  1985       Impact factor: 1.730

4.  The impact of the AIDS Drug Assistance Program (ADAP) on use of highly active antiretroviral and antihypertensive therapy among HIV-infected women.

Authors:  Thomas Yi; Jennifer Cocohoba; Mardge Cohen; Kathryn Anastos; Jack A DeHovitz; Naoko Kono; David B Hanna; Nancy A Hessol
Journal:  J Acquir Immune Defic Syndr       Date:  2011-03-01       Impact factor: 3.731

5.  Impact of Health Insurance, ADAP, and Income on HIV Viral Suppression Among US Women in the Women's Interagency HIV Study, 2006-2009.

Authors:  Christina Ludema; Stephen R Cole; Joseph J Eron; Andrew Edmonds; G Mark Holmes; Kathryn Anastos; Jennifer Cocohoba; Mardge Cohen; Hannah L F Cooper; Elizabeth T Golub; Seble Kassaye; Deborah Konkle-Parker; Lisa Metsch; Joel Milam; Tracey E Wilson; Adaora A Adimora
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

6.  Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death.

Authors:  C Holkmann Olsen; A Mocroft; O Kirk; S Vella; A Blaxhult; N Clumeck; M Fisher; C Katlama; A N Phillips; J D Lundgren
Journal:  HIV Med       Date:  2007-03       Impact factor: 3.180

7.  Retention and attendance of women enrolled in a large prospective study of HIV-1 in the United States.

Authors:  Nancy A Hessol; Kathleen M Weber; Susan Holman; Esther Robison; Lakshmi Goparaju; Christine B Alden; Naoko Kono; D Heather Watts; Niloufar Ameli
Journal:  J Womens Health (Larchmt)       Date:  2009-10       Impact factor: 2.681

8.  Coping with prescription drug cost sharing: knowledge, adherence, and financial burden.

Authors:  Mary Reed; Richard Brand; Joseph P Newhouse; Joe V Selby; John Hsu
Journal:  Health Serv Res       Date:  2008-04       Impact factor: 3.402

9.  The effect of the Medicare Part D prescription benefit on drug utilization and expenditures.

Authors:  Wesley Yin; Anirban Basu; James X Zhang; Atonu Rabbani; David O Meltzer; G Caleb Alexander
Journal:  Ann Intern Med       Date:  2008-01-07       Impact factor: 25.391

10.  The Hawthorne Effect: a randomised, controlled trial.

Authors:  Rob McCarney; James Warner; Steve Iliffe; Robbert van Haselen; Mark Griffin; Peter Fisher
Journal:  BMC Med Res Methodol       Date:  2007-07-03       Impact factor: 4.615

View more
  5 in total

1.  A Descriptive Study of HIV Patients Highly Adherent to Antiretroviral.

Authors:  Nick Williams; Craig Mayer; Vojtech Huser
Journal:  AMIA Annu Symp Proc       Date:  2021-01-25

2.  Economic Barriers to Antiretroviral Therapy in Nursing Homes.

Authors:  Brianne L Olivieri-Mui; Benjamin Koethe; Becky Briesacher
Journal:  J Am Geriatr Soc       Date:  2019-12-12       Impact factor: 5.562

3.  Health care utilization and HIV clinical outcomes among newly enrolled patients following Affordable Care Act implementation in a California integrated health system: a longitudinal study.

Authors:  Derek D Satre; Sujaya Parthasarathy; Michael J Silverberg; Michael Horberg; Kelly C Young-Wolff; Emily C Williams; Paul Volberding; Cynthia I Campbell
Journal:  BMC Health Serv Res       Date:  2020-11-11       Impact factor: 2.655

4.  Medicare Part D and Cost-Sharing for Antiretroviral Therapy and Preexposure Prophylaxis.

Authors:  Chien-Wen Tseng; R Adams Dudley; Randi Chen; Rochelle P Walensky
Journal:  JAMA Netw Open       Date:  2020-04-01

5.  The Utilisation of Payment Models Across the HIV Continuum of Care: Systematic Review of Evidence.

Authors:  Tiago Rua; Daniela Brandão; Vanessa Nicolau; Ana Escoval
Journal:  AIDS Behav       Date:  2021-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.